Kelley Penraat

Company: Novartis AG

Job title: Director - Translational Medicine

Seminars:

Workshop B – Current Strategies for Immunomodulation & Immunosupression for AAV Gene Therapies 9:00 am

Effectively measuring cellular and humoral immune responses to the vector  Discussing the importance of precision medicine when tailoring immune regimens to patients  Improving physician education for administering AAV gene therapies to better react to adverse events  Identifying methods to predict patient reactogenicity to AAV gene therapies Developing antigen-specific immune regiments to move away from steroids Read more

day: Clinical Track - AM